Chemotherapy & Targeted Therapy

Chemotherapy and targeted therapy remain foundational systemic treatments in oncology, used across virtually every cancer type in curative, adjuvant, neoadjuvant, and palliative settings. SilverOak Health's Medical Oncology Day Unit administers a comprehensive range of systemic anticancer treatments within a purpose-designed, patient-centred environment staffed by oncology-trained nurses and pharmacists who ensure the safety, accuracy, and supportive care surrounding every treatment administration.

Conventional cytotoxic chemotherapy agents — including platinums, taxanes, anthracyclines, antimetabolites, and alkylating agents — work by disrupting DNA replication or cell division in rapidly proliferating cancer cells. Regimen selection is guided by tumour type, stage, molecular profile, performance status, and organ function, with dosing individualised and carefully monitored for toxicity. Anti-emetic protocols, growth factor support, and comprehensive patient education minimise treatment-related morbidity and unplanned hospital admissions.

Targeted therapy exploits specific molecular vulnerabilities unique to cancer cells. Tyrosine kinase inhibitors (TKIs) target driver mutations including EGFR, ALK, ROS1, BRAF, HER2, and KRAS G12C in lung and other cancers. CDK 4/6 inhibitors, PARP inhibitors, and PI3K inhibitors are used in breast and ovarian cancers with specific molecular profiles. Antibody-drug conjugates combine tumour-targeting antibody precision with potent cytotoxic payload delivery. Comprehensive molecular profiling of each patient's tumour using next-generation sequencing enables selection of the most appropriate targeted agent, with clinical trial enrolment offered wherever standard options have been exhausted.